Wire · opportunities
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk, based on results from the large SURPASS-CVOT trial showing non-inferiority and an 8% lower rate of cardiovascular death, heart attack, or stroke compared to Trulicity.
This Wire brief sits within Fusion42's coverage of Health, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You face a regulatory green light to promote Mounjaro as a solution that also cuts heart risks in type 2 diabetes, opening opportunities in cardiovascular care beyond sugar control. Rival products now compete on cardiovascular proof, so position your next moves around integrated patient outcomes.
◆ Coverage
20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Topics